Astatine-211 Research

Researchers at PNNL are automating the radiochemical processing of isotopes using astatine-211, a short-lived alpha-emitting isotope. This research partnership with the University of Washington, from a DOE Isotope Program research grant, is developing an active solvent extraction process that results in more consistent quality. It has entered clinical trials.

Biological Targeting and In Vivo Delivery Systems

Targeted Alpha-Therapy

PNNL developed and patented high-affinity, high-selectivity chelators for radium-223 and actinium-225, in collaboration with the University of Washington and the University of Idaho.

• Radiolabeling of proteins

Alternative in vivo isotope delivery systems

PNNL developed alternative delivery systems for certain classes of poorly vascularlized tumor or for well-localized solid tumor masses.

• Radiolabeled microspheres
• Injectable polymers that are liquid at room temperature and become a gel at body temperature